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Flexibility of interval between vaccinations
with AS03A-adjuvanted influenza A (H1N1) 2009
vaccine in adults aged 18–60 and >60 years:
a randomized trial
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Abstract
Background: Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine
coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic
vaccine containing half of the registered adult haemagglutinin (HA) antigen content, administered as a two-dose
schedule at intervals of 21 days or 6 months in both young and elderly adults.
Methods: In this open-label randomized trial, healthy adults aged 18–60 years (N = 163) and >60 years (N = 143)
received AS03A-adjuvanted A/California/7/2009 H1N1 vaccine containing 1.9 μg HA on Day 0. A second dose was
given on Day 21 (n = 177) or Day 182 (n = 106). Haemagglutination-inhibition (HI) antibody responses were analyzed
on Days 0, 21, 42, 182, 364 and additionally on Day 203 for subjects vaccinated on Day 182. Solicited and
unsolicited adverse events were recorded.
Results: The HI antibody response in both age strata 21 days after the first dose met and exceeded all regulatory
acceptance criteria although the results suggested a lower response in the older age stratum (geometric mean
titres [GMTs] for HI antibodies of 420.5 for subjects aged 18–60 years and 174.4 for those >60 years). A second dose
of AS03A adjuvanted A/H1N1/2009 vaccine induced a further increase in antibody titres and the response was
similar whether the second dose was administered at 21 days (GMTs of 771.8 for 18–60 years and 400.9 for
>60 years) or 6 months (GMTs of 708.3 for 18–60 years and 512.1 for >60 years) following the first dose.
Seroprotection rates remained high at 6 months after one dose or two doses while at 12 months rates tended to
be higher for the 6 month interval schedule (93.3% for 18–60 years and 80.4% for >60 years) than the 21 day
schedule (82.3% for 18–60 years and 50.0% for >60 years). Reactogenicity/safety profiles were similar for both
schedules, there was no evidence of an increase in reactogenicity following the second dose.
Conclusions: The results indicate that flexibility in the dosing interval for AS03A adjuvanted vaccine may be
possible. Such flexibility could help to reduce the logistic stress on delivery of pandemic vaccination programmes.
Trial registration: ClinicalTrials.gov, NCT00975884
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Background
Influenza A viruses are responsible for annual seasonal
epidemics in humans when a limited number of muta-
tions occur (drift) and for influenza pandemics when,
following a substantial number of mutations or gene
segment reassortment (shift), a new variant of influenza
virus emerges against which humans have poor or no
existing immunity. The highly pathogenic avian influ-
enza A H5N1 strain has been circulating in several
countries during the last few years and, although not
readily transmissible, new drift variants are continuously
emerging which could acquire more efficient human to
human transmission [1].
Vaccination remains the most effective method for
preventing influenza infection [2] despite the compli-
cated logistics of large scale pandemic vaccination cam-
paigns. Two particular challenges for pandemic vaccines
are to achieve immunogenicity with the lowest antigen
content, given the limited global influenza antigen
manufacturing capacity [3] and to maximise the cross-
reactive potential of pandemic antigen against possible
drift strains.
During development of vaccines against avian H5N1,
adjuvant technology was successfully applied to address
these challenges. Inclusion of the α-tocopherol oil-in-
water emulsion based Adjuvant System AS03 enhanced
the immunogenicity of H5N1 vaccines thereby reducing
the amount of HA antigen required to 3.75 μg per dose
of vaccine [4]. AS03 also stimulated cross-immunity
against drifted H5N1 strains [4,5] and induced pro-
tection against heterologous lethal H5N1 challenge in
ferrets [6]. As AS03 adjuvanted H5N1 formulations
demonstrated a clinically acceptable safety profile [7,8],
the AS03 Adjuvant System was incorporated in the pan-
demic vaccine produced in response to the emergence
of A/H1N1/2009 virus. AS03-adjuvanted A/H1N1/2009
vaccine was authorised for use at an HA antigen dose of
3.75 μg for adults and 1.9 μg for children [9,10] in mass
vaccination campaigns in many countries.
In order to increase vaccine availability, an expansion
of manufacturing capacity and/or further reductions in
vaccine antigen content may be required. Another issue
was the logistics of administration of two doses of vac-
cine given 21 days apart which was the initial schedule
recommended based on experience with H5N1 vaccine.
Flexibility in this schedule, permitting an increase in the
dosing interval, could help to increase vaccine coverage
during the initial phase of a pandemic when vaccine
supplies may be limited. An increase in dosing interval
could potentially promote persistence of antibodies
over a longer period which may be an advantage during
prolonged circulation of a pandemic virus. A recent
study showed that one dose of AS03-adjuvanted H5N1
vaccine, followed by a single-adjuvanted heterologous
booster 12 months later elicited immune responses that
met all US and European criteria for both strains after
the booster dose [11].
Immunogenicity data has indicated that unlike H5N1,
one dose of A/H1N1/2009 vaccine is sufficient to elicit a
satisfactory immune response in most age groups
[9,10,12-16]. However, planning for future pandemics still
needs to anticipate the possibility of a two dose schedule
as the number of doses required may depend on the
nature of the pandemic strain and will not be known until
the immunogenicity profile has been established.
We report on the immune response and safety in both
young and elderly adults of AS03 adjuvanted A/Califor-
nia/7/2009 H1N1 vaccine containing half of the antigen
content per dose (1.9 μg instead of 3.75 μg HA) regis-
tered for adults but maintaining the same level of adju-
vant as in the registered adult dose. In addition we
assessed the flexibility of the administration schedule at
21 days or 6 months interval. An interval of 6 months
was selected based on previous experience with AS03
adjuvanted H5N1 vaccine [17].
Methods
Study design and participants
This was a phase III open, randomized trial with two
groups conducted in five centres in France from
September 2009 to April 2010. The primary objective
was to demonstrate that vaccination with one dose of A/
H1N1/2009 vaccine containing 1.9 μg of HA adjuvanted
with AS03A results in a haemagglutination-inhibition
(HI) immune response that meets or exceeds European
Medicines Agency (EMA) Committee for Medicinal Pro-
ducts for Human Use (CHMP) criteria for pandemic vac-
cines 21 days post vaccination [18]. Secondary objectives
included the assessment of immunogenicity following
administration of a second dose at Day 21 or Day 182,
assessment of persistence of the antibody response at
Day 182 and Day 364, and assessment of reactogenicity
and safety.
Eligible participants enrolled by the responsible on-site
personnel were clinically healthy non-pregnant adults
over 18 years of age at the time of the first vaccination
who provided written informed consent. Subjects with a
clinical history suggestive of an influenza infection within
6 months preceding the study start were excluded. The
enrolment was age-stratified, with two age strata (18–
60 years and >60 years, in 1:1 ratio) with a minimum of
40% of subjects aged 18–40 years and a minimum of
40% of subjects aged 41–60 years, in the 18–60 years
stratum; and a minimum of 40% of subjects aged 61–
70 years and a minimum of 20% of subjects aged above
70, in the >60 years stratum.
In the initial study design, all subjects were to be vac-
cinated on Day 0 and Day 21, however, the protocol was
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amended soon after the enrolment of the first subjects
(and before Day 21 was reached for these subjects) to in-
clude a Day 0 and Day 182 immunization schedule. This
amendment provided the opportunity to investigate the
immune response 6 months after a single A/H1N1/2009
vaccine injection and to assess the flexibility of the
vaccination schedule. The list of vaccinated subject
numbers which was tracked using the central random-
isation system on Internet (SBIR) and was randomised
(1:1) by the sponsor using SAS version 9.2 to receive a
second dose at either Day 21 (Group A) or Day 182
(Group B) taking into account the minimisation proced-
ure for centre and age. At Day 21, the subjects were
asked by the responsible on-site personnel to consent to
either receive a second vaccination at Day 21 as initially
planned or to be randomly assigned to a Day 21 or Day
182 second dose administration.
The protocol, its amendments and other relevant
study documentation were approved by the appropriate
Ethics Committee (CPP 1, Ile de France) and the study
was conducted in accordance with good clinical practice
guidelines, the Declaration of Helsinki and all applicable
regulatory requirements.
Study vaccine
The monovalent influenza A/H1N1/2009 inactivated,
split-virion vaccine was manufactured by GlaxoSmith-
Kline (GSK) Vaccines from a vaccine seed virus pre-
pared from the reassortant virus NYMC X-179A (New
York Medical College, New York) generated from the A/
California/7/2009 strain as recommended by the World
Health Organization (WHO) [19]. The seed virus was
propagated in embryonated hen eggs and the vaccine
was produced using the licensed manufacturing process
for Pandemrix™ (a trade mark of the GlaxoSmithKline
group of companies). AS03A is an Adjuvant System con-
taining α-tocopherol and squalene in an oil-in-water
emulsion (11.86 mg α-tocopherol) manufactured by
GSK Vaccines. The study vaccine was formulated to
contain 1.9 μg of HA antigen and AS03A [note that the
standard dose registered for adults contains 3.75 μg of
HA and AS03A while the paediatric dose contains 1.9 μg
of HA and AS03B (5.93 mg α-tocopherol)].
Procedures
A dose of AS03A-adjuvanted vaccine (0.38 ml injection
volume in this trial) was administered intramuscularly in
the deltoid region on Day 0 and either on Day 21 or Day
182 (according to subject consent to be randomly
assigned or not on Day 21 to one of the two schedules).
Blood samples were collected on Day 0 (prior to vaccin-
ation), Day 21, Day 42 and Day 182, Day 364 and add-
itionally for Group B only, on Day 203. All samples were
tested under blind conditions n a validated micro-titre
HI test using chicken erythrocytes as previously
described [20] with the A/California/7/2009 strain used
as antigen.
Data on solicited symptoms experienced within the
first 7 days following each vaccination were recorded on
diary cards by participants as previously described [21].
Data were also collected on the occurrence of any un-
solicited adverse events occurring within 21 days after
the first vaccination and either 63 days after the second
vaccination (for the 21 days interval schedule group) or
30 days after the second vaccination (for the 6 months
interval schedule group). The intensities of symptoms
and adverse events were recorded according to a stand-
ard three-grade scale as previously described [21]. An
assessment of causality was made by the investigator for
solicited systemic symptoms and unsolicited adverse
events. Data on serious adverse events, adverse events of
specific interest (AESIs) also called potential Immune-
Mediated Diseases (pIMDs) and adverse events of spe-
cial interest (convulsion and anaphylaxis) are planned to
be collected up to Day 546. This paper presents data up
until Day 364.
Statistical analysis
The analysis was descriptive. The immune response at
Day 21 addressing the primary objective was analysed
according to the standard EMA CHMP HI endpoints
[with 95% confidence intervals (CI)] used for evaluation
of influenza vaccines [18]. The sample size of 135 evalu-
able subjects per age strata (270 in total) was calculated
to give a power of at least 95% to fulfil the CHMP
criteria for these endpoints [18] following one dose of
vaccine. The immune response after the second dose
was also assessed for the same endpoints.
The safety endpoints (percentage of subjects and 95%
CI) were solicited adverse events and spontaneously
reported adverse events. All serious adverse events oc-
curring up to Day 364 were described. The statistical
analysis was performed using SAS Version 9.2.
Safety was assessed in the Total Vaccinated Cohort in-
cluding all subjects who received at least one dose
of vaccine. Immunogenicity was assessed in the per
protocol population including subjects without protocol
violation and with serological data at each immunogen-
icity time point (Day 21, Day 42, Day 182, Day 203
(Group B), and Day 364).
Results
Study population
A total of 306 subjects were vaccinated with AS03A-
adjuvanted A/H1N1/2009 vaccine on Day 0. Of these,
177 subjects received a 2nd dose on Day 21 (group A)
and 106 subjects received a 2nd dose on Day 182 (group
B). The stratification according to age led to the initial
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vaccination of 163 subjects aged 18 to 60 years and of
143 subjects aged over 60 years. Figure 1 shows the trial
profile and Additional file 1: Table S1 provides the
cohorts and rationale for exclusions from the immuno-
genicity assessment at each timepoint. The demographic
profiles for the per-protocol analysis of immunogenicity
for each group were similar with respect to age at first
dose vaccination (38.9 and 41.2 years and 66.6 and
66.3 years for the two age strata for groups A and B,
respectively) gender distribution (approximately 1:1) and
geographic ancestry (mainly white Caucasian).
Immune response
The HI antibody responses following both schedules in
adults aged 18 to 60 years and above 60 years are pre-
sented in Table 1 and Figure 2.
Prior to vaccination the percentages of subjects with
pre-existing HI antibody levels ≥1:40 (considered to be
seroprotective) were 14.4% for subjects aged <18–
60 years and 5.1% for subjects aged >60 years older
adults and pre-vaccination Geometric Mean Titres
(GMTs) in seropositive subjects were low in both age
groups (28.1 and 16.3).
The HI response in both age strata on Day 21 follow-
ing the first dose of vaccine met and exceeded all Euro-
pean CHMP regulatory acceptance criteria (as well as
CBER criteria) for influenza vaccines and so the primary
objective of the study was achieved. The results sug-
gested a lower immune response in the older age
stratum (GMTs of 459.8 for 18–60 year olds and 168.2
for above 60 year olds for pooled groups). Further strati-
fication by age suggested slightly lower GMTs with ad-
vancing age at all time-points (data not shown).
In group A, a second dose administered at Day 21 to
177 subjects induced a further increase in HI GMTs at
Day 42 in both age strata (from 459.8 after the first vac-
cination to 771.8 for the 18–60 years group and from
168.2 after the first vaccination to 400.9 for the
>60 years group). In group B, at 42 days after a single
vaccine dose, GMT values had decreased only marginally
compared to the previous time point.
HI antibodies still persisted at 6 months (Day 182)
with GMTs of 240.5 (18 to 60 years) and 97.8
(>60 years) in the group that had received two doses
(group A) and 124.1 (18–60 years) and 48.6 (>60 years)
in the group that had only received a single dose up to
that time-point (group B). Despite the decline in GMTs,
the percentages of subjects with putatively seroprotective
antibody levels at 6 months following administration of
either one (85.7% and 63.3% of the 18–60 years and the
>60 years groups, respectively) or two vaccine doses
(97.6% and 90.4% of the 18–60 years and >60 years
groups, respectively) still complied with European regu-
latory criteria (also for seroconversion rates and
geometric mean fold rises) and except for the older age
stratum who received only one dose, still also complied
with US regulatory criteria.
A second dose administered at 6 months (Day 182)
interval to 106 subjects induced a further increase of
GMTs 21 days later (on Day 203) in both age strata
(708.3 for 18–60 years and 512.1 for >60 years). The
GMTs induced by a second dose were similar whether
administered at Day 21 or at 6 months interval.
HI antibody persistence at study month 12 (Day 364)
tended to be higher for the 6 month interval group B
(GMTs and seroprotection rates were respectively 155.5
and 93.3% for 18–60 years and 68.8 and 80.4% for
>60 years) than for the 21 day interval group A (GMTs
and seroprotection rates were respectively 107.8 and
82.3% for 18–60 years and 35.8 and 50.0% for
>60 years).
Reactogenicity and safety
The incidence of solicited local (injection site) and systemic
symptoms reported per group within 7 days after each
vaccination are presented in Tables 2 and 3 respectively.
The profile and frequencies of solicited symptoms
were similar in both study groups. No difference in pro-
file or increase in the frequencies of solicited symptoms
could be distinguished with the administration of a sec-
ond dose in either vaccination schedule. The observed
incidences of certain solicited symptoms were slightly
numerically higher in the subjects aged 18–60 years.
Pain at the injection site was the most common soli-
cited symptom reported following vaccination in both
younger adults (94.6% and 95.7% after a first dose and
87.9% and 90% after a second dose in group A (Day 0 -
Day 21 vaccinations) and group B (Day 0 - Day 182 vac-
cinations, respectively) and among adults aged
>60 years (78.9% and 67.3% after a first dose and 72.9%
and 57.8% after a second dose in groups A and B,
respectively). Most injection site related symptoms were
mild to moderate with a maximum of three subjects per
age stratum reporting grade 3 pain or redness or swel-
ling greater than 100 mm after any vaccination. The
most frequently reported solicited systemic symptoms
were fatigue (maximum 53.8% after a second dose at
Day 21, 18–60 years stratum), muscle aches (maximum
51.7% after a second dose at Day 182, 18–60 years
stratum) and headache (maximum 45.1% after a second
dose at Day 21, 18–60 years stratum). Grade 3 systemic
symptoms were rare (0 to 4 subjects for any one of these
symptoms after every dose).
In group A the percentage of subjects reporting
unsolicited adverse events (data not shown) within
21 days after the first vaccination and 63 days after the
second vaccination was 55.9% of the 18–60 year age
group (12.9% of these events were considered as related
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Figure 1 Trial Profile.
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Table 1 Immune response for haemagglutination-inhibition (HI) antibodies against A/California/7/2009 H1N1 in adults aged 18 to 60 years and in adults
>60 years (per-protocol immunogenicity cohorts)
N Seroprotection rate
(titre ≥ 1:40) % (95% CI)
Seroconversion
rate* % (95% CI)
Geometric Mean
Fold Rise** (95% CI)
N Seroprotection rate
(titre ≥ 1:40) % (95% CI)
Seroconversion
rate* % (95% CI)
Geometric Mean
Fold Rise** (95% CI)
Vaccinated on Day 0 (subjects from Groups A and B pooled) 18–60 years Vaccinated on Day 0 (subjects from Groups A and B pooled) >60 years
Day 0 (Prevaccination) 160 14.4 - - 136 5.1 - -
(9.3-20.8) (2.1-10.3)
Day 21 160 97.5 96.3 45.0 136 91.9 89.0 23.4
(93.7-99.3) (92.0-98.6) (37.3-54.5) (86.0-95.9) (82.5-93.7) (19.1-28.7)
Group A Vaccinated on Day 0 and Day 21
18-60 years
Group A Vaccinated on Day 0 and Day 21
>60 years
Day 0 (Prevaccination) 87 12.6 - - 83 7.2 - -
(6.5-21.5) - (2.7-15.1)
Day 21 87 100 100 51.6 83 90.4 89.2 23.0
(95.8-100) (95.8-100) (40.7-65.5) (81.9-95.7) (80.4-94.9) (17.7-29.9)
Day 42 87 100 98.9 86.7 83 100 98.8 54.9
(95.8-100) (93.8-100) (68.6-109.5) (95.7-100) (93.5-100) (43.4-69.3)
Day 182 85 97.6 92.9 26.6 83 90.4 86.7 13.4
(91.8-99.7) (85.3-97.4) (20.8-34.0) (81.9-95.7) (77.5-93.2) (10.9-16.5)
Day 203 - - - - - -
Day 364 79 82.3 75.9 11.0 76 50.0 40.8 4.8
(72.1-90.0) (65.0-84.9) (9.2-15.5) (38.3-61.7) (29.6-52.7) (3.8-6.1)
Group B Vaccinated on Day 0 and Day 182
18–60 years
Group B Vaccinated on Day 0 and Day 182
>60 years
Day 0 (Prevaccination 67 14.9
(7.4-25.7)
- - 48 2.1
(0.1-11.1)
- -
Day 21 67 94.0 92.5 39.2 48 95.8 89.6 23.3
(85.4-98.3) (83.4-97.5) (28.3-54.2) (85.7-99.5) (77.3-96.5) (16.6-32.7)
Day 42 67 95.5 91.0 31.9 48 89.6 81.3 16.5
(87.5-99.1) (81.5-96.6) (23.4-43.4) (77.3-96.5) (67.4-91.1) (11.8-23.0)
Day 182 56 85.7 83.9 14.6 30 63.3 56.7 6.1
(73.8-93.6) (71.7-92.4) (10.8-19.7) (43.9-80.1) (37.4-74.5) (3.9-9.4)
Day 203 48 100 100 79.0 28 100 100 65.7
(92.6-100) (92.6-100) (58.0-107.7) (87.7-100) (87.7-100) (41.4-104.1)
Day 364 60 93.3 90.0 17.3 46 80.4 73.9 8.3
(83.8-98.2) (79.5-96.2) (13.0-23.0) (66.1-90.6) (58.9-85.7) (6.0-11.3)
*Seroconversion rate for haemagglutination-inhibition antibody response is defined as the percentage of vaccinees who have a prevaccination titre <1:10 and a post-vaccination titre ≥1:40, or a significant increase in
antibody titre defined as the percentage of vaccinees who have a pre-vaccination titre ≥ 1:10 and at least a fourfold increase in post-vaccination titre. **Geometric mean fold rise is defined as geometric mean of the
within-subject ratios of the post-vaccination reciprocal haemagglutination-inhibition titre to the Day 0 reciprocal agglutination-inhibition titre.
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) criteria for haemagglutination-inhibition antibody response in 18–60 year olds are: seroprotection rate >70%, seroconversion rate
>40%, and geometric mean fold rise >25 and in adults >60 years are seroprotection rate >60%, seroconversion rate >30%, and geometric mean fold rise >20.
United States Center for Biologics Evaluation and Research (CBER) criteria for hemagglutination-inhibition antibody response in adults <65 years are: lower limit (LL) of 95% CI for seroprotection ≥70% and LL of 95% CI
for seroconversion ≥40% and in adults ≥65 years are LL of 95% CI for seroprotection ≥60% and LL of 95% CI for seroconversion ≥30%.
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to vaccination) and 58.2% of the >60 year age group
(16.5% considered as related to vaccination). In group B
the percentage of subjects reporting unsolicited adverse
events (data not shown) within 21 days after the first
vaccination and 30 days after the second vaccination was
50.0% in the 18–60 year age group (18.6% considered as
related to vaccination) and 30.8% in the >60 year age
group (9.6% considered as related to vaccination). The
most frequently reported adverse events were rhinitis,
nasopharyngitis and bronchitis. Grade 3 adverse events
were reported by 10.8% of subjects aged 18–60 years
(none considered as related to vaccination) and 9.9% of
subjects aged >60 years (1.1% considered as related to
vaccination) in group A and by 8.6% of subjects aged
18–60 years (4.3% considered as related to vaccination)
and 3.8% of subjects aged >60 years (1.9% considered as
related to vaccination) in group B.
Over the Day 0 to Day 364 study period reported here,
nineteen serious adverse events were reported of which
two were considered by the investigator as related to the
vaccination. A 63 year-old female experienced hepatic
enzyme increase at 21 days after the first vaccination;
this was resolved on Day 42. The second event was a
Herpes zoster infection reported 18 days following the
second dose and resolved 22 days later.
There was one withdrawal from the study due to a
non-serious adverse event. Up to Day 364, two pIMDs
were reported (ankylosing spondylitis 157 days after the
2nd dose and multiple sclerosis 37 days after the 2nd
dose). Neither event was considered by the investigator
to be related to vaccination. There were two events of
special interest reported: multiple sclerosis and urticaria.
The urticaria event, reported on day 1 after the 1st dose,
was considered by the investigator to be related to vac-
cination and resolved 15 days later.
Discussion
The results of this study indicate that for adults aged 18
to 60 years and elderly adults over 60 years the dosing
interval between vaccinations with AS03A-adjuvanted
influenza A (H1N1) 2009 vaccine could be flexible.
The genetic variability of influenza A viruses means
that the characteristics of the next pandemic influenza
strain are not predictable; it could be a return of H2N2,
a variant of the swine-origin A/H1N1/2009 strain or cur-
rently circulating H3N2, a more transmissible variant of
the avian-origin H5, H9, or H7 subtypes or a completely
novel strain. It is important therefore to build up a
knowledge base from data generated with A/H1N1/2009,
H5N1 and other subtype vaccines which could be poten-
tially relevant to development of new pandemic vaccines.
Even though a single dose of A/H1N1/2009 vaccine
appeared to be sufficient to fulfil regulatory criteria for
2009 pandemic influenza vaccine [9,10,12-16], this may
not be the case for future pandemic influenza strains
depending on how antigenically and genetically distinct
they are from strains which have previously circulated
in humans. It has already been shown that for the
avian H5N1 influenza strain, two doses of vaccine are
required to elicit a satisfactory response [4], although a
recent study showed that two heterologous doses given
12 months apart elicited immune responses that met all
US and European criteria for both H5N1 vaccine strains
after the booster dose [11]. This observation concurs
with data generated with AS03A adjuvanted A/Vietnam/
1194/2004 (H5N1) vaccine which showed that two doses
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Figure 2 Geometric mean titres (with 95% confidence intervals) for haemagglutination inhibition antibodies against A/California/7/
2009 in adults aged 18 to 60 years and in adults >60 years (per-protocol immunogenicity cohorts). Group A= Vaccination on Day 0
and Day 21; Group B = Vaccination on Day 0 and Day 182.
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given 6 months apart achieved equivalent seroprotection
after the second vaccination when compared to two
doses given 21 days apart [17]. Furthermore, when im-
munity against the heterologous A/Indonesia/05/2005
H5N1 strain was measured, the group vaccinated at
0 and 6 months achieved an even higher cross-reactive
response after the last vaccination, when compared with
the group vaccinated at 0 and 21 days [17]. In our study
the cross-reactive responses were not investigated for
the two schedules as no antigenically drifted strain from
the A/H1N1/2009 strain has yet been isolated. In terms
of antibody persistence although at 12 months following
the first dose, the seroprotection rates tended to be
higher for the 0 and 6 months schedule, about 80% of
18–60 year olds and 50% of the over 60 year olds vacci-
nated according to the 0 and 21 day schedule still had
seroprotective antibody levels at 12 months.
Previous studies have shown that when combined with
AS03A adjuvant, one dose of A/H1N1/2009 vaccine con-
taining 3.75 μg of HA antigen is sufficient to induce a
response meeting regulatory criteria for influenza vac-
cines in adults at 21 days following vaccination [10,22].
In this study the immune response induced by one dose
of AS03A adjuvanted A/H1N1/2009 vaccine containing
the lower antigen content of 1.9 μg HA has met and
exceeded all European and US regulatory criteria in both
younger (18–60 years) and older (above 60 years) adults.
Furthermore at six months following administration of
one vaccine dose containing 1.9 μg HA, even though
antibody levels had declined, seroprotective rates still
complied with European criteria and also with US cri-
teria for younger adults. These data suggested that use
of AS03A adjuvant may allow the vaccine antigen con-
tent to be further reduced below 3.75 μg HA. Although
Table 2 Percentage (with 95% confidence intervals) of subjects reporting solicited local (injection site) symptoms
within 7 days after the first and after the second dose of H1N1 vaccine in adults aged 18 to 60 years and in adults
>60 years
Symptom Intensity Group A Vaccinated on Day 0 and Day 21 Group B Vaccinated on Day 0 and Day 182
Dose 1% (95% CI)
18-60 years N= 92 >60 years N= 90 18-60 years N= 70 >60 years N= 52
Pain Any 94.6 78.9 95.7 67.3
(87.8-98.2) (69.0-86.8) (88.0-99.1) (52.9-79.7)
Grade 3* 0.0 2.2 0.0 0.0
(0.0-3.9) (0.3-7.8) (0.0-5.1) (0.0-6.8)
Redness Any 10.9 8.9 11.4 1.9
(5.3-19.1) (3.9-16.8) (5.1-21.3) (0.0-10.3)
>100 mm 0.0 0.0 0.0 0.0
(0.0-3.9) (0.0-4.0) (0.0-5.1) (0.0-6.8)
Swelling Any 12.0 6.7 8.6 1.9
(6.1-20.4) (2.5-13.9) (3.2-17.7) (0.0-10.3)
>100 mm 0.0 0.0 0.0 0.0
(0.0-3.9) (0.0-4.0) (0.0-5.1) (0.0-6.8)
Dose 2% (95% CI)
18-60 years N= 91 >60 years N= 85 18-60 years N= 60 >60 years N= 45
Pain Any 87.9 72.9 90.0 57.8
(79.4-93.8) (62.2-82.0) (79.5-96.2) (42.2-72.3)
Grade 3* 2.2 0.0 5.0 0.0
(0.3-7.7) (0.0-4.2) (1.0-13.9) (0.0-7.9)
Redness Any 6.6 12.9 10.0 6.7
(2.5-13.8) (6.6-22.0) (3.8-20.5) (1.4-18.3)
>100 mm 0.0 0.0 3.3 2.2
(0.0-4.0) (0.0-4.2) (0.4-11.5) (0.1-11.8)
Swelling Any 8.8 11.8 16.7 8.9
(3.9-16.6) (5.8-20.6) (8.3-28.5) (2.5-21.2)
>100 mm 0.0 0.0 0.0 0.0
(0.0-4.0) (0.0-4.2) (0.0-6.0) (0.0-7.9)
*Grade 3 was defined as significant injection site pain at rest which prevents normal activities (inability to attend/do work).
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Table 3 Percentage of subjects (with 95% confidence intervals) reporting solicited systemic symptoms within 7 days
after the first and after the second dose of H1N1 vaccine in adults aged 18 to 60 years and in adults >60 years
Symptom Intensity Group A Vaccinated on Day 0 and Day 21 Group B Vaccinated on Day 0 and Day 182
Dose 1% (95% CI)
18-60 years N=92 >60 years N= 90 18-60 years N= 70 >60 years N= 52
Fatigue Any 43.5 28.9 38.6 34.6
(33.2-54.2) (19.8-39.4) (27.2-51.0) (22.0-49.1)
Grade 3* 0.0 0.0 1.4 0.0
(0.0-3.9) (0.0-4.0) (0.0-7.7) (0.0-6.8)
Headache Any 37.0 22.2 31.4 17.3
(27.1-47.7) (14.1-32.2) (20.9-43.6) (8.2-30.3)
Grade 3* 0.0 1.1 1.4 0.0
(0.0-3.9) (0.0-6.0) (0.0-7.7) (0.0-6.8)
Joint pain at other location Any 22.8 21.1 14.3 15.4
(14.7-32.8) (13.2-31.0) (7.1-24.7) (6.9-28.1)
Grade 3* 0.0 0.0 0.0 0.0
(0.0-3.9) (0.0-4.0) (0.0-5.1) (0.0-6.8)
Muscle aches Any 46.7 28.9 32.9 28.8
(36.3-57.4) (19.8-39.4) (22.1-45.1) (17.1-43.1)
Grade 3* 0.0 0.0 0.0 1.9
(0.0-3.9) (0.0-4.0) (0.0-5.1) (0.0-10.3)
Shivering Any 18.5 13.3 20.0 11.5
(11.1-27.9) (7.1-22.1) (11.4-31.3) (4.4-23.4)
Grade 3* 0.0 1.1 0.0 0.0
(0.0-3.9) (0.0-6.0) (0.0-5.1) (0.0-6.8)
Sweating Any 13.0 11.1 10.0 13.5
(6.9-21.7) (5.5-19.5) (4.1-19.5) (5.6-25.8)
Grade 3* 1.1 0.0 0.0 0.0
(0.0-5.9) (0.0-4.0) (0.0-5.1) (0.0-6.8)
Fever (Axillary temp) Any 1.1 1.1 2.9 1.9
(0.0-5.9) (0.0-6.0) (0.3-9.9) (0.0-10.3)
≥39.0 to ≤40°C 0.0 0.0 0.0 0.0
(0.0-3.9) (0.0-4.0) (0.0-5.1) (0.0-6.8)
Dose 2% (95% CI)
18-60 years N=91 >60 years N= 85 18-60 years N= 60 >60 years N= 45
Fatigue Any 53.8 31.8 51.7 29.5
(43.1-64.4) (22.1-42.8) (38.4-64.8) (16.8-45.2)
Grade 3* 3.3 1.2 3.3 0.0
(0.7-9.3) (0.0-6.4) (0.4-11.5) (0.0-8.0)
Headache Any 45.1 22.4 35.0 25.0
(34.6-55.8) (14.0-32.7) (23.1-48.4) (13.2-40.3)
Grade 3* 1.1 1.2 5.0 0.0
(0.0-6.0) (0.0-6.4) (1.0-13.9) (0.0-8.0)
Joint pain at other location Any 19.8 24.7 26.7 27.3
(12.2-29.4) (16.0-35.3) (16.1-39.7) (15.0-42.8)
Grade 3* 0.0 0.0 0.0 0.0
(0.0-4.0) (0.0-4.2) (0.0-6.0) (0.0-8.0)
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this observation is specific to A/H1N1/2009 and would
also have to be ascertained for other strains such as
H5N1, it merits further investigation in the context of
potential antigen shortage. Further studies would how-
ever need to include a control group administered with
3.75 μg HA to ascertain the impact on the magnitude of
the antibody response and persistence, particularly in
older adults where the response tended to be lower than
in younger adults. Older adults also tend to have weaker
immune responses to non-adjuvanted seasonal influenza
vaccines than younger adults and this has been attribu-
ted to a decline in immune function with increasing age
[23-25]. Inclusion of oil in water based emulsion adju-
vants however has been shown to improve the immuno-
genicity of seasonal [26], H5N1 [27] and A/H1N1/2009
influenza vaccines [30] in the elderly.
A limitation of the study was that the population in Group
B beyond Day 21 was below the pre-specified 135 subjects
needed to demonstrate that immunogenicity fulfilled the
CHMP criteria with 95% power. Although the immunogen-
icity endpoints fulfilled the licensure criteria in Group B at
Day 182 and Day 203, it should be noted that the per proto-
col populations at these time points comprised 86 and 76
subjects, respectively. Although subjects with a medical his-
tory suggesting influenza during the six months prior to the
study were excluded, seroprotection rates of 14% for adults
aged 18 to 60 years and 5% for adults aged over 60 years
were recorded prior to vaccination. The presence of baseline
antibodies against A/H1N1/2009 has also been documented
in other studies [12-14,21]. As Hancock et al. [28] concluded
that recent seasonal influenza vaccines induced little or no
cross-reactive antibody responses to A/H1N1/2009, these
baseline antibodies might be due to asymptomatic A/H1N1/
2009 infections prior to the study start (September 2009). It
has also been speculated that some older adults may have
been exposed to strains closely related to A/H1N1/2009
which were in circulation over 60 years ago [28,29].
The AS03 Adjuvant System has previously been admi-
nistered with H5N1 vaccines in a two-dose schedule to
a large number of adults in clinical studies [7,8] and
more recently with A/California/7/2009 H1N1 vaccine
as a single-dose schedule in mass vaccination cam-
paigns in many countries. Consistent with other pub-
lished clinical studies on AS03 adjuvanted A/California/
7/2009 H1N1 [10,21,22] or H5N1 vaccines [7,8] the
most common solicited symptoms following vaccination
in this present study in adults aged 18 to 60 years and
over 60 years were injection site pain, fatigue, headache,
and muscle aches which were mainly mild to moderate
in nature.
Reactogenicity was within the same range after the
first and after the second vaccine dose whether or not
they were 21 days or 6 months apart and also for both
study groups. These observations indicated that different
vaccination schedules (one or two doses, dosing intervals
of 21 days or 6 months for a second dose) may not
impact on reactogenicity which is in line with previous
experience with AS03 adjuvanted H5N1 vaccine [17].
Conclusions
The results indicate that flexibility in the dosing interval
for AS03A adjuvanted vaccine which could help to reduce
Table 3 Percentage of subjects (with 95% confidence intervals) reporting solicited systemic symptoms within 7 days
after the first and after the second dose of H1N1 vaccine in adults aged 18 to 60 years and in adults >60 years
(Continued)
Muscle aches Any 42.9 29.4 51.7 34.1
(32.5-53.7) (20.0-40.3) (38.4-64.8) (20.5-49.9)
Grade 3* 0.0 0.0 1.7 0.0
(0.0-4.0) (0.0-4.2) (0.0-8.9) (0.0-8.0)
Shivering Any 28.6 15.3 18.3 15.9
(19.6-39.0) (8.4-24.7) (9.5-30.4) (6.6-30.1)
Grade 3* 1.1 1.2 0.0 0.0
(0.0-6.0) (0.0-6.4) (0.0-6.0) (0.0-8.0)
Sweating Any 20.9 16.5 13.3 9.1
(13.1-30.7) (9.3-26.1) (5.9-24.6) (2.5-21.7)
Grade 3* 1.1 0.0 0.0 0.0
(0.0-6.0) (0.0-4.2) (0.0-6.0) (0.0-8.0)
Fever (Axillary temp) Any 6.6 5.9 1.7 0.0
(2.5-13.8) (1.9-13.2) (0.0-8.9) (0.0-8.0)
≥39.0 to ≤40°C 0.0 2.4 0.0 0.0
(0.0-4.0) (0.3-8.2) (0.0-6.0) (0.0-8.0)
*Grade 3 events were defined as events that prevent normal everyday activities (inability to attend/do work), or that require intervention of a physician/
healthcare provider.
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the logistic stress on delivery of pandemic vaccination
programmes may be possible if a two-dose vaccination
policy is required. Potential reduction of antigen content
to 1.9 μg HA may also be of interest in the context of
potential antigen shortage.
Additional file
Additional file 1: Table S1. Number of subjects enrolled and number
of subjects excluded from per-protocol cohort analysis with rationale for
exclusion at each time point.
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